Replimune (REPL) Interest Expenses (2019 - 2026)
Replimune (REPL) posted Interest Expenses of $3.6 million for Q1 2026, down 91.3% sequentially from $41.6 million in Q4 2025, and up 3221.55% YoY from $109015.3 in Q1 2025.
Analysis
Replimune (REPL) Interest Expenses (2019 - 2026) Analysis & Trends
Replimune has reported Interest Expenses for 10 years, with the latest figure at $3.6 million in Q1 2026.
- Quarterly Interest Expenses rose 3221.55% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.9 million (up 95.01% YoY) and the FY2026 annual result came in at $312.0 million, up 40.79% from the prior year.
- Interest Expenses fell to $3.6 million in Q1 2026 per REPL's latest filing, from $41.6 million in the prior quarter.
- Over five years, Interest Expenses peaked at $51.0 million in Q2 2022 and troughed at -$242000.0 in Q1 2022.
- A 5-year average of $33.2 million and a median of $44.4 million in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2026: Interest Expenses tumbled 232.97% in 2022, then soared 3221.55% in 2026.
- Over 5 years, Interest Expenses stood at $49.7 million in 2022, then declined by 5.27% to $47.1 million in 2023, then slipped by 5.73% to $44.4 million in 2024, then dropped by 6.26% to $41.6 million in 2025, then plunged by 91.3% to $3.6 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $3.6 million, $41.6 million, and $42.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Replimune | 1.45 Bn | 1.45 Bn | - | 2.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.58 Mn |
| Mar 31, 2026 | 2.37 Mn |
| Dec 31, 2025 | 1.47 Mn |
| Sep 30, 2025 | 1.49 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 1.46 Mn |
| Dec 31, 2024 | 1.45 Mn |
| Sep 30, 2024 | 1.44 Mn |
| Jun 30, 2024 | 1.43 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 955,000.00 |
| Jun 30, 2023 | 1.12 Mn |
| Mar 31, 2023 | 1.02 Mn |
| Dec 31, 2022 | 941,000.00 |
| Mar 31, 2021 | 1,000.00 |
| Dec 31, 2020 | 247,000.00 |
| Sep 30, 2020 | 286,000.00 |
| Jun 30, 2020 | 284,000.00 |
| Mar 31, 2020 | -295,000.00 |